Get the Stockscreener App
4.25
4.94%
+0.20
Pre-market:
4.12
-0.13
-3.06%
COMPANY PROFILE
NameAbeona Therapeutics
SectorHealthcare (1499)
IndustryBiotechnology (867)
Web
Phone646 813 4701
Employee90
Twitter
@abeonabio
SEC filings
Latest SEC Filings
Address1330 Avenue of the Americas, 33rd Floor, New York, NY, United States (10019)
News
Price History
Option Chain
Financials
Insider Trading
Why ABEO Down?
Discussions
Forecast
Stock Split
Dividend History
Abeona Therapeutics Stock (ABEO) Latest News
GlobeNewswire Inc.
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
GlobeNewswire Inc.
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
GlobeNewswire Inc.
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
GlobeNewswire Inc.
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
GlobeNewswire Inc.
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
GlobeNewswire Inc.
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
GlobeNewswire Inc.
Abeona Therapeutics Joins Rare Disease Company Coalition
GlobeNewswire Inc.
Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.
Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.
Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101
PennyStocks
3 Penny Stocks To Watch Before Next Week; Time To Buy?
GlobeNewswire Inc.
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
GlobeNewswire Inc.
Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
About Abeona Therapeutics
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Cap:
|
Volume (24h):